

Key takeaways: Financial diligence on a testing or QC lab rarely shows its operational risk. Accreditation scope, instrument condition, data integrity and key-person dependency can each erase value after close. A two-week operational review using the 12 checks below surfaces most of it before signing.
Testing, inspection and certification labs and outsourced QC labs are attractive targets: recurring revenue, regulatory moats and fragmented markets ripe for roll-ups. But a lab's value sits on assets the financial model barely sees, such as its accreditation, its instruments, its data and a handful of people who hold critical methods in their heads. Here are the red flags that most often surprise buyers after close.
Compare the revenue mix to the lab's scope of accreditation, test by test. Revenue from methods not on scope is at risk if customers require accredited results.
Ask for the last two or three assessment reports and customer audit reports. One finding is normal. The same finding across cycles signals a quality system that fixes symptoms, not causes.
Most accreditation bodies require notification of changes in ownership or legal status and may reassess. Biopharma QC labs may also need to update customer quality agreements and regulatory registrations. Build the timeline into the deal plan.
Repeated unsatisfactory proficiency testing results are an early warning that results may not hold up, and accreditation bodies treat them seriously.
Map critical instruments against manufacturer end-of-support dates. A fleet that looks fully depreciated may hide a large capex wall in years one to three.
Overdue calibrations and deferred maintenance flatter short-term margins and create both compliance and downtime risk.
Reported utilization often ignores downtime, calibration windows and qualification constraints. True available capacity determines whether the growth plan is realistic without new capex.
Count how many analysts are authorized on each revenue-critical method. If one or two people hold a high-margin method, that's a retention and continuity risk.
Look for shared logins, disabled audit trails, results kept in uncontrolled spreadsheets and paper worksheets transcribed by hand. In GMP labs these are inspection risks. In any lab they are customer trust risks.
Instrument controllers often run outdated operating systems that can't be patched without revalidation. Assess the cybersecurity exposure and the cost to remediate.
Retests, reruns and corrections consume labor, consumables and capacity without new revenue. Few labs report this rate, so ask for it directly.
Compare promised and actual turnaround time by customer and test type. Chronic delays drive churn that won't show in historical revenue until it's too late.
Accreditation is granted to a legal entity at specific sites. A change of ownership usually requires notifying the accreditation body, which decides whether a reassessment is needed. Plan for it early.
A focused review of the areas above can usually be completed in about two weeks with access to the right records and people.
Key-person dependency and instrument end-of-support are often missed because neither shows up in financial statements.
Evaluating a lab acquisition? Trucision gives deal and operating teams a fast, record-level view of instrument health, compliance status and capacity. Book a 30-minute call.